About the ESMO Handbook of Interpreting Oncological Study Publications
AACR |
American Association for Cancer Research |
ADME |
Absorption, distribution, metabolism and excretion |
AR |
Adaptive randomisation |
ASCO |
American Society of Clinical Oncology |
AUC |
Area under the curve |
BOR |
Best overall response |
CENTRAL |
Cochrane Central Register of Controlled Trials |
CI |
Confidence interval |
CLL |
Chronic lymphoid leukaemia |
Cmax |
Maximum serum concentration |
CMF |
Cyclophosphamide, methotrexate and 5-fluorouracil regimen |
COMET |
Core Outcome Measures in Effectiveness Trials |
COS |
Core outcome set |
CR |
Complete response |
CR30 |
Complete response at 30 months |
CRC |
Colorectal cancer |
CT |
Computed tomography |
DCIS |
Ductal carcinoma in situ |
DCO |
Death certificate only |
DFS |
Disease-free survival |
DoR |
Duration of response |
DSS |
Disease-specific survival |
ECCO |
European Cancer Organisation |
ECOG |
Eastern Cooperative Oncology Group |
EFS |
Event-free survival |
EFS24 |
Event-free survival at 24 months |
EMA |
European Medicines Agency |
ENCR |
European Network of Cancer Registries |
EORTC |
European Organisation for Research and Treatment of Cancer |
ESMO |
European Society for Medical Oncology |
EU |
European Union |
FDA |
Food and Drug Administration |
FDG-PET |
Fludeoxyglucose–positron emission tomography |
FLASH |
Follicular Lymphoma Analysis of Surrogacy Hypothesis |
GCP |
Good Clinical Practice |
G-CSF |
Granulocyte-colony stimulating factor |
GEMMs |
Genetically engineered mouse models |
GI |
Gastrointestinal |
GLP |
Good Laboratory Practice |
GMP |
Good Manufacturing Practice |
GRADE |
Grading of Recommendations, Assessment, Development and Evaluation |
HBV |
Hepatitis B virus |
HIPEC |
Hyperthermic intraperitoneal chemotherapy |
HR |
Hazard ratio |
HR-QoL |
Health-related quality of life |
HRT |
Hormone replacement therapy |
HTS |
High throughput screening |
IACR |
International Association of Cancer Registries |
IARC |
International Agency for Research on Cancer |
ICD-O |
International Classification of Diseases for Oncology |
LMS |
Leiomyosarcoma |
MAMS |
Multi-arm, multistage |
MISCAN |
MIcrosimulation SCreening ANalysis |
mRCC |
Metastatic renal cell carcinoma |
MRD |
Minimal residual disease |
MTD |
Maximum tolerated dose |
NCI |
National Cancer Institute |
NNS |
Number needed to screen |
NSCLC |
Non-small cell lung cancer |
OBD |
Optimum biological dose |
OR |
Odds ratio |
ORR |
Objective/overall response rate |
OS |
Overall survival |
PET |
Positron emission tomography |
PFS |
Progression-free survival |
PICO |
Population, Interventions or exposures, Comparators and Outcomes |
PORT |
Postoperative radiotherapy |
PPR |
Prior pelvic irradiation |
PR |
Partial response |
PROM |
Patient-Reported Outcome Measures |
PULA |
Previously Untreated, Locally Advanced Task Force |
PVNS |
Pigmented villonodular synovitis |
RCT |
Randomised controlled trial |
RoB |
Risk of Bias |
RR |
Relative risk, Risk ratio |
SD |
Standard deviation |
SLL |
Small lymphocytic lymphoma |
STROBE |
Strengthening the Reporting of Observational Studies in Epidemiology |
STS |
Soft tissue sarcoma |
T1/2 |
Half-life |
TNM |
Tumour, Node, Metastasis classification |
TTF |
Time to treatment failure |
TTP |
Time to progression |
UICC |
Union for International Cancer Control |
US |
United States |
VEGF(R) |
Vascular endothelial growth factor (receptor) |
WHO |
World Health Organization |
